Bioavailability following oral administration of a silibinin-phosphatidylcholine complex in cats

International Journal of Applied Research in Veterinary Medicine

Volumn 10, Issue 2, 2010, Pages 107-112

  Webb, Craig B ^a   Gustafson, Daniel L ^a   Twedt, David C ^a  

^a Veterinary Dentistry and Oral Surgery   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FELIDAE;

EID: 84864397990     PISSN: 15422666     EISSN: 1559470X     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Center SA, Warner KL, Erb HN. Liver glutathione concentrations in dogs and cats with naturally occurring liver disease. Am J Vet Res 2000;63:1187-1197.
2. Wellington K, Jarvis B. Silymarin: a review of its clinical properties in the management of hepatic disorders. BioDrugs 2001;15:465-489.
3. Flora K, Hahn M, Rosen H, et al. Milk thistle (Silybum marianum) for the therapy of liver disease. Am J Gastroenterol 1998;93:139-143.
4. Fuchs EC, Weyhenmeyer R, Weiner OH. Effects of silibinin and of a synthetic analogue on isolated rat heaptic stellate cells and myofbroblasts. Arz-neimittelforschung 1997;47: 1383-1387.
5. Jia JD, Bauer M, Cho JJ, et al. Antifbrotic effect of silymarin in rat secondary biliary fibrosis is mediated by downregulation of procollagen alpha1(I) and TIMP-1. J Hepatol 2001;35:392-398.
6. Di Sario A, Bendia E, Taffetani S, et al. Hepatoprotective and antifbrotic effect of a new siybin-phos-phatidylcholine-Vitamin E complex in rats. Dig Liv Dis 2005;37:869-876.
7. Dehmlow C, Erhard J, de Groot H. Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibinin. Hepatol 1996;23:749-745.
8. Sonnenbichler J, Goldberg M, Hane L, et al. Stimulatory effect of Silibinin on the DNA synthesis in partially hepatectomized rat livers: non-response in hepatoma and other malign cell lines. Biochem Pharm 1986;35:538-541.
9. Sonnenbichler J, Zetl I. Biochemical effects of the favonolignane silibinin on RNA, protein and DNA synthesis in rat livers. Prog Clin BiolRes 1986;213:319-313.
10. Crocenzi FA, Roma MG. Silymarin as a new hepatoprotective agent in experimental cholestasis: new possibilities for an ancient medication. Curr Med Chem 2006;13:1055-1074.
11. Polyak SJ, Morishima C, Shuhart MC, et al. Inhibition of T-cell infammatory cytokines, hepatocyte NF-kappaB signaling, and HCV infection by standardized Silymarin. Gastroenterol 2007;132:1925-1936.
12. Salmi HA, Sarna S. Effect of silymarin on chemical, functional, and morphological alterations of the liver. Scand J of Gastroenterol 1982;17:5-10.
13. Pár A, Róth E, Rumi G, et al. [Oxidative stress and antioxidant defense in alcoholic liver disease and chronic hepatitis C]. Orvosi Hetilap, 2000;141:1655-1659.
14. Garrido A, Arancibia A, Campos R, et al. Acetaminophen does not induce oxidative stress in isolated rat hepatocytes: its probable antioxidant effect is potentiated by the favinoid silybin. Pharm Tox 1991;69:9-12.
15. Barzaghi N, Crema F, Gatti G, et al. Pharmacoki-netic studies in a silybin-phosphatidylcholine complex complex IdB 1016 in healthy human subjects. Eur J Drug Metabol Pharm 1990;15:333-338.
16. Magliulo E, Gagliardi B, Fiori GP. Zur wirkung von silymarin bei der behandlung der akuten virushepatitis. Med Klinik 1978;73:1060-1065.
17. Carini R, Comoglio A, Albano E, et al. Lipid peroxidation and irreversible damage in the rat hepatocyte model. Protection by the silybin-phospholipid complex IdB 1016. Biochem Pharm 1992;43:2111-2115.
18. Filburn CR, Kettenacker R, Griffn D. Safety and bioavailability in Beagles of zinc and vitamin E combined with silybin and phosphatidylcholine. Int J App Res Vet Med 2006;4:326-334.
19. Filburn CR, Kettenacker R, Griffn DW. Bioavail-ability of a silybin-phosphatidylcholine complex in dogs. J Vet Pharm Ther 2007;30:132-138.
20. Flaig TW, Gustafson DL, Su L-J, et al. A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients. Invest New Drugs, 2007;25:139-146.
21. Muriel P, Garciapiña T, Perez-Alvarez V, et al. Silymarin protects against paracetamol-induced lipid peroxidation and liver damage. J App Tox 1992;12:439-442.
22. Paulová J, Dvorák M, Kolouch F, et al. [Verifcation of the hepatoprotective and therapeutic effect of silymarin in experimental liver injury with tetrachloromethane in dogs]. Vet Med (Praha), 1990;35:629-635.
23. Pietrangelo A, Montosi G, Garuti C, et al. Iron-induced oxidant stress in nonparenchymal liver cells: mitochondrial derangement and fibrosis in acutely iron-dosed gerbils and its prevention by silybin. J Bioenerg Biomem 2002;34:67-70.
24. Vogel G, Tuchweber B, Trost W, et al. Protection by silibinin against Amanita phalloides intoxication in beagles. Tox App Pharm 1984;73:355-362.
25. Manach C, Donovan JL. Pharmacokinetics and metabolism of dietary favonoids in humans. Free Rad Res 2004;38:771-785.
26. Manach C, Williamson G, Morand C, et al. Bio-availability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am J Clin Nutrition 2005;81:230S-242S.
27. Schandalik R, Gatti G, Perucca E. Pharmacokinetics of silybin in bile following administration of silipide and silymarin in cholecystectomy patients. Arzneimittelforschung 1992;42:964-968.
28. Gatti G, Perucca E. Plasma concentrations of free and conjugated silybin after oral intake of a silybin-phosphatidylcholine complex (silipide) in healthy volunteers. Int J Clin Pharm Ther 1994;32:614-617.
29. Flory PJ, Krug G, Lorenz D, et al. Studies on elimination of silymarin in cholecystectomized patients. I. Biliary and renal elimination after a single oral dose. Planta Medica 1980;38:227-237.
30. Lorenz D, Lücker PW, Mennicke WH. Pharmaco- kinetic studies with silymarin in human serum and bile. Meth Find Exp Clin Pharm 1984;6:655-661.
31. Saller R, Meier R, Brignoli R. The use of silymarin in the treatment of liver diseases. Drugs 2001;61:2035-2063.
32. Gazák R, Walterová D, Kren V. Silybin and silymarin-new and emerging applications in medicine. Curr Med Chem 2007;14:315-338.
33. Agarwal R, Agarwal C, Ichikawa H, et al. Anticancer potential of silymarin: from bench to bed side. Anticancer Res 2006;26:4457-4498.
34. Soto C, Mena R, Luna J, et al. Silymarin induces recover of pancreatic function after alloxan damage in rats. Life Sci 2004;75:2167-2180.